Literature DB >> 25031741

Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population.

Xia Liu1, Yong Guan2, Wei Zhang2, Shan Liu2, Junjun Liu2, Li Wang2, Yun Niu2.   

Abstract

To establish a series of objective parameters to predict the risk of relapse from axillary lymph node-negative (ANN) breast cancer, and evaluate the patterns of recurrence according to molecular subtypes, we collected information on 2126 consecutive breast cancer patients operated between 2002 and 2006. In this case-control study, 212 patients experiencing recurrence or breast cancer related death were defined as 'poor group'. Another 212 patients were selected from the remaining cases with stratified sampling method to comprise the 'good group'. Significant differences were found in vascular invasion, grade and molecular subtype between the two groups. Expression of ER and PR in the 'poor group' was lower (P < 0.05). However, positive rates of Ki67, p53 and VEGF in the 'poor group' were higher (P < 0.05). Multivariate analysis revealed that molecular subtype, expression of VEGF, tumor grade, and vascular invasion were closely correlated with bad outcome. Analysis of the 'poor group' demonstrated that 'HER2 positive' and 'triple negative' subtypes more commonly suffered from distant metastases and death. No metastasis was found in patients with pure invasive papillary carcinoma, invasive cribriform carcinoma or adenoid cystic carcinoma, whereas the diagnoses of invasive micropapillary carcinoma, invasive apocrine carcinoma, invasive papillary carcinoma mixed with invasive ductal carcinoma, or metaplastic carcinoma were correlated with distant metastasis and death. In conclusion, molecular subtype and expression of VEGF are useful markers for predicting prognosis of ANN breast cancer patients. 'Luminal A-like' subtype has better outcome than others. Moreover, molecular subtypes have different recurrence patterns.

Entities:  

Keywords:  Breast cancer; VEGF; molecular subtype; p53; recurrence

Mesh:

Substances:

Year:  2014        PMID: 25031741      PMCID: PMC4097226     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Authors:  Yahong Wang; Quangui Yin; Qi Yu; Jing Zhang; Ziyu Liu; Shuling Wang; Shuhua Lv; Yun Niu
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

2.  Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

Authors:  Rita Abi-Raad; Rimoun Boutrus; Rui Wang; Andrzej Niemierko; Shannon Macdonald; Barbara Smith; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-21       Impact factor: 7.038

3.  Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.

Authors:  Rachel L Theriault; Jennifer K Litton; Elizabeth A Mittendorf; Huiqin Chen; Funda Meric-Bernstam; Mariana Chavez-Macgregor; Phuong K Morrow; Wendy A Woodward; Aysegul Sahin; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Clin Breast Cancer       Date:  2011-07-20       Impact factor: 3.225

4.  Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study.

Authors:  Carla Suzanne Fisher; David J Cole; Michael Mitas; Elizabeth Garrett-Meyer; John S Metcalf; William E Gillanders; Kaidi Mikhitarian; Marshall M Urist; G Bruce Mann; Gerard Doherty; Virginia M Herrmann; Arnold D Hill; Oleg Eremin; Mohamed El-Sheemy; Richard K Orr; Alvaro A Valle; Michael A Henderson; Robert L Dewitty; Sonia L Sugg; Eric Frykberg; Karen Yeh; Richard M Bell; Megan K Baker
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

5.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

6.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

Review 7.  VEGF-targeted therapy: mechanisms of anti-tumour activity.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Nat Rev Cancer       Date:  2008-07-03       Impact factor: 60.716

8.  The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

Authors:  Shelley B Bull; Hilmi Ozcelik; Dushanthi Pinnaduwage; Martin E Blackstein; Donald A J Sutherland; Kathleen I Pritchard; Anjela T Tzontcheva; Saul Sidlofsky; Wedad M Hanna; Ali H Qizilbash; Mary E Tweeddale; Sheldon Fine; David R McCready; Irene L Andrulis
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

9.  Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials.

Authors:  Jos A van der Hage; J Sven D Mieog; Cornelis J H van de Velde; Hein Putter; Harry Bartelink; Marc J van de Vijver
Journal:  Breast Cancer Res       Date:  2011-06-24       Impact factor: 6.466

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more
  3 in total

1.  Single nucleotide polymorphisms in VEGF gene are associated with an increased risk of osteosarcoma.

Authors:  Zhang Tie; Rui Bai; Zhongwen Zhai; Gang Zhang; Hong Zhang; Zhenqun Zhao; Deshan Zhou; Wanlin Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 2.  Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.

Authors:  Shuyang Yao; Funda Meric-Bernstam; David Hong; Filip Janku; Aung Naing; Sarina Anne Piha-Paul; Apostolia Maria Tsimberidou; Daniel Karp; Vivek Subbiah; Timothy Anthony Yap; Jordi Rodon Ahnert; Shubham Pant; Ecaterina E Ileana Dumbrava; Chetna Wathoo; Erick Campbell; Lihou Yu; Yuko Yamamura; Siqing Fu
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

3.  Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.

Authors:  Jin-Luan Li; Xiao-Yi Lin; Li-Juan Zhuang; Jun-Yan He; Qing-Qin Peng; Ya-Ping Dong; Jun-Xin Wu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.